Bhattacharyya Sutanay, Gupta Vipul
Nephrology, Neotia Getwel Multispecialty Hospital, Siliguri, IND.
Nephrology, Fortis Hospital, Ludhiana, IND.
Cureus. 2025 Jun 5;17(6):e85409. doi: 10.7759/cureus.85409. eCollection 2025 Jun.
Gallstone disease (GSD) is a known but relatively underrecognized complication in renal transplant (RT) recipients, particularly in those receiving cyclosporine. However, there is scarce data on the association between tacrolimus use and cholelithiasis. We present the case of a 33-year-old female with end-stage renal disease who underwent an ABO-compatible RT and was initiated on a standard triple immunosuppressive regimen consisting of tacrolimus (3.5 mg/day), mycophenolate mofetil (1.5 g/day), and prednisolone (20 mg/day). Six weeks post-transplant, she developed acute abdominal pain, nausea, and right upper quadrant tenderness with a positive Murphy's sign. Abdominal ultrasonography revealed multiple gallstones, the largest measuring 8 mm. She was managed conservatively and notably lacked traditional risk factors for gallstone formation. Pre-transplant imaging had not revealed any biliary abnormalities. Tacrolimus as a cause of GSD remains underreported. This report highlights the need for increased clinical awareness and further research to understand its potential role in post-transplant biliary complications.
胆结石病(GSD)是肾移植(RT)受者中一种已知但相对未被充分认识的并发症,尤其是在接受环孢素治疗的患者中。然而,关于使用他克莫司与胆石症之间关联的数据却很少。我们报告一例33岁终末期肾病女性患者,她接受了ABO血型相容的肾移植,并开始采用由他克莫司(3.5毫克/天)、霉酚酸酯(1.5克/天)和泼尼松龙(20毫克/天)组成的标准三联免疫抑制方案。移植后六周,她出现急性腹痛、恶心以及右上腹压痛,墨菲氏征阳性。腹部超声检查发现多个胆结石,最大的直径为8毫米。她接受了保守治疗,并且明显缺乏胆结石形成的传统危险因素。移植前的影像学检查未发现任何胆道异常。他克莫司作为胆结石病的病因仍未得到充分报道。本报告强调需要提高临床认识并开展进一步研究,以了解其在移植后胆道并发症中的潜在作用。